UniQure, Syndax, Erasca Drawing Fresh Analyst Interest
Three clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Choosing between Sp500 and Total Market funds can shape your retirement. This guide compares performance, diversification, and allocation to help you decide.
28,514 articlesThree clinical-stage biotechs—UniQure, Syndax, and Erasca—are catching analyst attention ahead of key catalysts, with...
Bitcoin holds around $60,000 as geopolitical tensions between the US and Iran intensify. Most altcoins drift lower wh...
A senior executive recently reduced his stake in CATY by one third through an open market sale. This article explains...
Bitcoin steadies around the mid-50s as XRP, Solana, and PEPE push higher on evolving policy signals and renewed inves...
Capri Holdings saw a notable insider purchase when the CEO bought 55,000 shares. This article breaks down what it cou...
Move, operator of Realtor.com, delivered a 10% year‑over‑year revenue gain in News Corp’s Q3 results. The broader com...
Nebius Group delivered a blowout Q1 2026, with revenue growth of 684% and a high-stakes push from NVIDIA and Meta, tr...
Bitcoin prices declined as investors rotated toward safer assets, marking a negative week for digital asset funds. Ye...
The SEC is moving to enable tokenized stocks on crypto platforms, potentially ushering in 24/7 on-chain trading and n...
Corporate treasuries are redefining crypto investing. This deep dive looks at how Strategy amassed a sizable Bitcoin ...
The U.S. market is blazing, but a surprising nation has surged 10x U.S. stock gains since early 2025. Here's what inv...
As Bausch Health prepares its Q4 2025 results, investors want clarity on margins, debt, and the pipeline. This guide ...